Shares across Asia jumped following developments overnight regarding the use of Gilead Sciences' antiviral drug Remdesivir as a potential new treatment for Covid-19 patients. Sentiment also improved after China said manufacturing activity in the country expanded slightly in April.
Buying was also triggered after foreign portfolio investors (FPIs) turned net buyers of Indian equities on Wednesday (29 April). FPIs bought shares worth a net Rs 722.08 crore on 29 April 2020, as per provisional data released by the stock exchanges. Domestic institutional investors (DIIs) bought shares worth a net Rs 78.67 crore on 29 April 2020, as per provisional data.
In the broader market, the S&P BSE Mid-Cap index was up 2.02% while the S&P BSE Small-Cap index rose 2.04%. Both these indices trailed the Sensex.
The market breadth was strong. On the BSE, 1467 shares rose and 723 shares fell. A total of 131 shares were unchanged. In Nifty 50 index, 47 stocks advanced while 3 stocks declined.
Q4 Results Today:
Reliance Industries (up 3%), Hindustan Unilever (down 1.68%), Tech Mahindra (up 2.3%), ABB Power Products (up 0.26%), Aditya Birla Money (up 3.54%), Laurus Labs (fell 0.27%) and Security and Intelligence Services (up 1.06%) are some of the companies that will announce their quarterly result today, 30 April 2020.
Derivatives:
The NSE's India VIX, a gauge of market's expectation of volatility over the near term, fell 1.2% to 33.43. The Nifty April 2020 futures were trading at 9,850.80, a discount of 13.05 points compared with the spot at 9,863.85.
On the options front, the Nifty option chain for 30 April 2020 expiry showed maximum call open interest (OI) of 54.45 lakh contracts at the 10,000 strike price. Maximum put OI of 43.33 lakh contracts was seen at 9,700 strike price.
Stocks in Spotlight:
Morepen Laboratories advanced 3.77% to Rs 18.44 after the company said it received ISO-13485 certification for its medical devices manufacturing facility at Baddi in Himachal Pradesh. e certification has been awarded for the manufacturing, distribution and after sales service of all point-of-care diagnostic medical devices and their accessories manufactured at the company's facility in Baddi.
Polycab India was locked in an upper circuit of 5% at Rs 724.8 after the company said that the board of directors have scheduled a meeting on 2 May 2020 to consider and approve convening of board meeting to consider and approve the proposal for investment/acquisition of shares.
Lupin said its Pithampur Unit-1 facility received EIR from the US drug regulator for its Pithampur Unit-1, India facility. The inspection for the facility was conducted by the USFDA between 3rd and 11th February 2020 and concluded with two observations. Lupin was down 1.19% at Rs 844.10.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
